CA2348907A1 - Schema posologique analgesique - Google Patents
Schema posologique analgesique Download PDFInfo
- Publication number
- CA2348907A1 CA2348907A1 CA002348907A CA2348907A CA2348907A1 CA 2348907 A1 CA2348907 A1 CA 2348907A1 CA 002348907 A CA002348907 A CA 002348907A CA 2348907 A CA2348907 A CA 2348907A CA 2348907 A1 CA2348907 A1 CA 2348907A1
- Authority
- CA
- Canada
- Prior art keywords
- tramadol
- days
- day
- titration
- regimen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000000202 analgesic effect Effects 0.000 title description 9
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 claims abstract description 91
- 229960004380 tramadol Drugs 0.000 claims abstract description 90
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 claims abstract description 90
- 238000011282 treatment Methods 0.000 claims abstract description 20
- 230000036592 analgesia Effects 0.000 claims abstract 7
- PPKXEPBICJTCRU-XMZRARIVSA-N (R,R)-tramadol hydrochloride Chemical compound Cl.COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 PPKXEPBICJTCRU-XMZRARIVSA-N 0.000 claims description 24
- 229960003107 tramadol hydrochloride Drugs 0.000 claims description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 6
- 238000004448 titration Methods 0.000 abstract description 50
- 230000000694 effects Effects 0.000 abstract description 16
- 238000002560 therapeutic procedure Methods 0.000 abstract description 11
- 206010028813 Nausea Diseases 0.000 description 17
- 206010047700 Vomiting Diseases 0.000 description 17
- 230000002411 adverse Effects 0.000 description 17
- 230000008693 nausea Effects 0.000 description 17
- 230000008673 vomiting Effects 0.000 description 16
- 239000003814 drug Substances 0.000 description 15
- 208000002193 Pain Diseases 0.000 description 14
- 229940079593 drug Drugs 0.000 description 14
- 230000001684 chronic effect Effects 0.000 description 13
- 230000004083 survival effect Effects 0.000 description 11
- 230000001186 cumulative effect Effects 0.000 description 9
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 9
- 239000000902 placebo Substances 0.000 description 9
- 229940068196 placebo Drugs 0.000 description 8
- 208000000094 Chronic Pain Diseases 0.000 description 7
- 208000002173 dizziness Diseases 0.000 description 7
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 208000006820 Arthralgia Diseases 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 4
- 208000012886 Vertigo Diseases 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 231100000889 vertigo Toxicity 0.000 description 4
- 229940035676 analgesics Drugs 0.000 description 3
- 239000000730 antalgic agent Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 206010041349 Somnolence Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 238000001325 log-rank test Methods 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 230000003533 narcotic effect Effects 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- TVYLLZQTGLZFBW-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol Chemical compound COC1=CC=CC(C2(O)C(CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 102000003840 Opioid Receptors Human genes 0.000 description 1
- 108090000137 Opioid Receptors Proteins 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003502 anti-nociceptive effect Effects 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000023611 glucuronidation Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000013284 inhibition of norepinephrine uptake Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- 229960004127 naloxone Drugs 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 239000003401 opiate antagonist Substances 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 230000000697 serotonin reuptake Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
L'invention concerne un schéma posologique d 'administration de tramadol, pour le traitement de la douleur. Le schéma posologique implique une vitesse d'administration initiale du tramadol inférieure, qui occasionne un pourcentage d'interruptions de la thérapie inférieur du fait que l'incidence et la gravité des effets secondaires sont réduites.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10656798P | 1998-11-02 | 1998-11-02 | |
| US60/106,567 | 1998-11-02 | ||
| PCT/US1999/023513 WO2000025769A1 (fr) | 1998-11-02 | 1999-10-12 | Schema posologique analgesique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2348907A1 true CA2348907A1 (fr) | 2000-05-11 |
Family
ID=22312128
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002348907A Abandoned CA2348907A1 (fr) | 1998-11-02 | 1999-10-12 | Schema posologique analgesique |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1126834A1 (fr) |
| CN (1) | CN1346266A (fr) |
| AR (1) | AR021054A1 (fr) |
| AU (1) | AU763273B2 (fr) |
| BR (1) | BR9914981A (fr) |
| CA (1) | CA2348907A1 (fr) |
| CZ (1) | CZ20011535A3 (fr) |
| EA (1) | EA003557B1 (fr) |
| HR (1) | HRP20010311A2 (fr) |
| HU (1) | HUP0104260A3 (fr) |
| NO (1) | NO20012133L (fr) |
| PL (1) | PL348808A1 (fr) |
| WO (1) | WO2000025769A1 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1905435A3 (fr) * | 2003-03-11 | 2008-05-14 | Euro-Celtique S.A. | Régime de dosage de titrage pour tramadol à libération contrôlée |
| US7413749B2 (en) * | 2003-03-11 | 2008-08-19 | Purdue Pharma L.P. | Titration dosing regimen for controlled release tramadol |
| US20060172006A1 (en) * | 2003-10-10 | 2006-08-03 | Vincent Lenaerts | Sustained-release tramadol formulations with 24-hour clinical efficacy |
| CN101252932B (zh) | 2005-09-09 | 2012-10-03 | 安吉利尼莱博法姆有限责任公司 | 用于一天给药一次的曲唑酮组合物 |
| CA3015420C (fr) * | 2016-02-29 | 2023-09-26 | Grunenthal Gmbh | Titrage de cebranopadol |
-
1999
- 1999-10-12 PL PL99348808A patent/PL348808A1/xx not_active Application Discontinuation
- 1999-10-12 EA EA200100501A patent/EA003557B1/ru not_active IP Right Cessation
- 1999-10-12 AU AU64224/99A patent/AU763273B2/en not_active Ceased
- 1999-10-12 HU HU0104260A patent/HUP0104260A3/hu unknown
- 1999-10-12 CN CN99814987A patent/CN1346266A/zh active Pending
- 1999-10-12 WO PCT/US1999/023513 patent/WO2000025769A1/fr not_active Application Discontinuation
- 1999-10-12 CZ CZ20011535A patent/CZ20011535A3/cs unknown
- 1999-10-12 EP EP99951876A patent/EP1126834A1/fr not_active Withdrawn
- 1999-10-12 CA CA002348907A patent/CA2348907A1/fr not_active Abandoned
- 1999-10-12 BR BR9914981-8A patent/BR9914981A/pt not_active IP Right Cessation
- 1999-11-01 AR ARP990105524A patent/AR021054A1/es unknown
-
2001
- 2001-04-30 NO NO20012133A patent/NO20012133L/no not_active Application Discontinuation
- 2001-05-02 HR HR20010311A patent/HRP20010311A2/hr not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20010311A2 (en) | 2002-06-30 |
| AU6422499A (en) | 2000-05-22 |
| HUP0104260A2 (en) | 2002-08-28 |
| AR021054A1 (es) | 2002-06-12 |
| CZ20011535A3 (cs) | 2002-08-14 |
| BR9914981A (pt) | 2001-10-30 |
| HUP0104260A3 (en) | 2002-11-28 |
| EA003557B1 (ru) | 2003-06-26 |
| PL348808A1 (en) | 2002-06-17 |
| NO20012133D0 (no) | 2001-04-30 |
| EA200100501A1 (ru) | 2001-10-22 |
| AU763273B2 (en) | 2003-07-17 |
| WO2000025769A1 (fr) | 2000-05-11 |
| CN1346266A (zh) | 2002-04-24 |
| NO20012133L (no) | 2001-07-02 |
| EP1126834A1 (fr) | 2001-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6339105B1 (en) | Analgesic regimen | |
| Gibson | Pharmacokinetics, efficacy, and safety of analgesia with a focus on tramadol HCl | |
| US8858963B1 (en) | Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia | |
| KR101618929B1 (ko) | 파킨슨병의 치료에 있어서 오피오이드 효능제와 오피오이드 길항제의 조합물 | |
| US9050335B1 (en) | Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia | |
| Ventafridda et al. | Non-steroidal antiinflammatory drugs as the first step in cancer pain therapy: double-blind, within-patient study comparing nine drugs | |
| KR101864559B1 (ko) | 정맥 내 투여용 이부프로펜의 투여 | |
| US20170216277A1 (en) | Therapeutic use of nalbuphine without aquaretic effects | |
| Freeman | The treatment of neuropathic pain | |
| AU763273B2 (en) | Analgesic regimen | |
| JPH10505087A (ja) | 非麻薬性鎮痛剤および無痛エンハンサーを含有する疼痛緩和組成物 | |
| Abel | Tramadol: an alternative analgesic to traditional opioids and NSAIDs | |
| CN116808038A (zh) | 阿片类物质和n-酰基乙醇胺的组合 | |
| CN112672743A (zh) | 肝病瘙痒症状的治疗 | |
| US20170087104A1 (en) | Medicament | |
| EP2830605A1 (fr) | Combinaison médicamenteuse comprenant la phényléphrine et le paracétamol | |
| MXPA01004414A (en) | Analgesic regimen | |
| US20040167146A1 (en) | Method of treatment | |
| JP4695326B2 (ja) | 鼻炎用医薬組成物 | |
| EA011926B1 (ru) | Пероральный антидепрессивный состав, включающий ацетилсалициловую кислоту для ускорения начала действия | |
| KR20230074469A (ko) | 경구 투여 제제 | |
| US20080125414A1 (en) | Method of Treatment | |
| JP2005533046A (ja) | 鎮痛薬の作用を増強するためにオピオイド鎮痛薬と併用するデバゼピドの使用 | |
| Rinnier et al. | Overview and antagonists of NMDA receptors | |
| JP2006327993A (ja) | 鎮痛薬 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |